Peripheral/Endo

Medtronic Closes $28M Purchase of QT Vascular’s Chocolate PTA Balloon Catheter

Medtronic Completes the Purchase of QT Vascular’s Chocolate PTA Balloon Catheter Highlights: – Medtronic completes the purchase of the Company’s non-drug coated Chocolate® PTA balloon catheter – The completion of this purchase validates the value of this internally developed specialty PTA to improve outcomes in patients with peripheral artery disease PLEASANTON, Calif., Jan. 29, 2018 /PRNewswire/ — QT […]

Medtronic Shows Off IN.PACT Global Critical Limb Ischemia Study Data

IN.PACT Admiral Demonstrates Consistent and Durable Outcomes in New Two-Year Japan Data and IN.PACT Global Critical Limb Ischemia Cohort Analysis Data Presented at LINC 2018 Highlight IN.PACT Admiral as Safe and Effective Treatment Option in PAD DUBLIN and LEIPZIG – January 30, 2018 – Medtronic (NYSE: MDT) today added to its robust body of clinical evidence supporting […]

Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

IRVINE, Calif.–(BUSINESS WIRE)– Endologix Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Greg Morrow as the Company’s Chief Marketing Officer, effective immediately. Mr. Morrow brings to Endologix a wealth of executive marketing experience in medical devices. Most recently, he led the Coronary Division and Marketing Function for […]

LimFlow Completes Enrollment In U.S. Feasibility Study and Receives Breakthrough Device Status from FDA for Its Percutaneous Deep Vein Arterialization (pDVA) System

Novel Technology is Designed to Restore Blood Flow to Ischemic Lower Limbs, Which May Resolve Pain, Help Wounds Heal and Avoid Major Amputation PARIS–(BUSINESS WIRE)– LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), today announced completion of enrollment of the original 10-patient cohort in the U.S. feasibility study of […]

Medtronic Launches IDE Study to Evaluate the Abre(TM) Venous Self-Expanding Stent System in Patients with Deep Venous Disease

Study to Enroll Subjects at up to 35 Sites Across the U.S. and Europe DUBLIN – January 26, 2018 – Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and effectiveness of the Abre stent […]

TOBA II BTK Trial Enrollment Ahead of Schedule for the Tack Endovascular System® in Below the Knee Disease

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) clinical trial surpassed the 100 patient milestone, advancing enrollment well ahead of schedule. The TOBA II BTK is a prospective, multi-center, single-arm study designed to […]

FDA Green Lights Surmodics’ Telemark Coronary/Peripheral Support Microcatheter

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)– SurModics (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Telemark™ .014” coronary and peripheral support microcatheter. The Company is making this product available for U.S. distribution in the coming months. The Telemark support microcatheter offers […]

Cardiovascular Systems Expands Product Portfolio to Further Support Peripheral and Coronary Interventions

ST. PAUL, Minn.–(BUSINESS WIRE)– Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced two new partnerships broadening the company’s product portfolio. CSI is now the exclusive U.S. distributor of OrbusNeich balloon products. Additionally, the company has signed an original […]

BD Announces Completion of Enrollment in the Lutonix 014 Drug Coated Balloon Below-the-Knee Trial

FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018. The Lutonix BTK trial is a prospective, multicenter, randomized, controlled trial intended to demonstrate […]

Secant Group Develops the First Synthetic Regenerative Cardiovascular Graft

TELFORD, Pa.–(BUSINESS WIRE)–Secant Group, in partnership with its sister company SanaVita Medical, announce game changing technology to advance cardiovascular regenerative medicine with the development of a synthetic, small bore, vessel that encourages endogenous regeneration and new vessel formation. The technology is based on the company’s sophisticated textile forming capabilities that can produce a hollow lumen […]